- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04888364
French Parkinson's Disease Cohort - NS-PARK (NS-PARK)
Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)
Visão geral do estudo
Status
Condições
Descrição detalhada
The national clinical research network for Parkinson's disease (NS-PARK/FCRIN) reassembles all expert centers in Parkinson's disease (PD) in France. Its aim is to promote clinical research in Parkinson's disease and movement disorder, to better understand the pathophysiology of PD, foster the development of new therapeutic strategies, and move towards personalized medicine. To help centers for prescreening, a national registry of PD patients followed in each centers has been implemented in 2016 to collect minimal relevant clinical information of patients followed in each center including demographic data, age at diagnosis, standardized motor and non-motor symptoms evaluation, and treatment. Data are updated at each visit of the patient in the center. De facto, this registry became a longitudinal cohort of PD patients followed in NS-PARK centers. In 2020, NS-PARK received funding to associate a biocollection to this clinical cohort.
The aim of NS-PARK cohort are to describe the natural history of PD progression in clinical routine in France, to develop new models of PD describing the different progression profiles, and to propose patients stratification based on PD pathophysiological mechanisms. The cohort will also serve as a platform to discover new PD genes and genetic modifiers of disease progression or response to treatment.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Contato de estudo
- Nome: Jean Christophe MD CORVOL, PU-PH
- Número de telefone: 33 1 42 16 57 66
- E-mail: jean-christophe.corvol@aphp.fr
Locais de estudo
-
-
-
Paris, França, 75013
- Recrutamento
- Centre 01 Paris
-
Contato:
- Jean Christophe MD Corvol, Pr
- Número de telefone: 33 1 42 16 57 66
- E-mail: jean-christophe.corvol@aphp.fr
-
Investigador principal:
- Jean Christophe MD Corvol, Pr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Diagnosis of Parkinson's disease according to UK PD brain bak criteria
- OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom
- OR Subjects at risk of PD defined as :
No symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015)
AND for all participants
- Affiliated to social security
- Age > 10 years
Exclusion Criteria:
- Subject under legal protection
- Subject who do not consent to the research
- for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Disease progression
Prazo: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Hoehn and Yahr score change
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Motor and non-motor complications
Prazo: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Occurence of motor (dyskinesia or motor fluctuations) or non-motor (dementia, dysautonomia, behavioral or psychiatric disorders, sleep disorders, falls, ...) complication
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Modification of antiparkinsonian treatment doses
Prazo: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Modification of antiparkinsonian treatment during follow-up will be measured as levodopa equivalent daily doses
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Predictive factorsof PD progression: motor or non motor symptoms
Prazo: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Motor or non motor symptoms as measured by MDS-UPDRS scores will be used as predictive factors for primary outcomes
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Predictive factors of PD progression: genetic variants
Prazo: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Genetic variants in PD genes or the Genetic PD risk score will be used as predictive factors for primary outcomes.
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Predictive factors of PD progression: brain imaging markers
Prazo: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Brain imaging makers (iron or neuromelanine content of the substantia nigra) will be used as predictive factors for primary outcomes
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Clusters of patients with similar disease progression profiles
Prazo: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Clustering analyses will be performed on disease progression markers (Hoehn and Yahr score, MDS-UPDRS scores, and doses of treatment (levodopa equivalent daily doses)) to identify homogeneous groups of patients (clusters) sharing similar disease progression profiles.
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Clusters of patients with similar genetic and disease progression profiles
Prazo: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Co-clustering analysis of disease progression markers (Hoehn and Yahr score, MDS-UPDRS scores, and doses of treatment (levodopa equivalent daily doses)) and genetic markers (variants in PD genes or the Genetic PD risk score).
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Genetic mutations associated with familal forms of PD
Prazo: through study completion, 15 years
|
Genetic mutations will be screened by different methods (gene panels, whole exome or whole genome) in familial forms of PD.
Mutations co-segregated with PD will be considered as potentially associated with the disease.
|
through study completion, 15 years
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Jean Christophe MD CORVOL, PU-PH, UMRS 1127
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- C16-56
- 2019-A01929-48 (Identificador de registro: RCB ID)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doença de Parkinson
-
ProgenaBiomeRecrutamentoDoença de Parkinson | Doença de Parkinson com Demência | Parkinson-Síndrome Demencial | Doença de Parkinson 2 | Doença de Parkinson 3 | Doença de Parkinson 4Estados Unidos
-
National Yang Ming UniversityDesconhecidoDoença de Parkinson de Início Precoce | Doença de Parkinson em estágio inicial
-
National Heart, Lung, and Blood Institute (NHLBI)ConcluídoDoença de Parkinson 6, de início precoce | Doença de Parkinson (Autossômica Recessiva, Início Precoce) 7, Humana | Doença de Parkinson Autossômica Recessiva de Início Precoce | Doença de Parkinson, Autossômica Recessiva de Início Precoce, Digênica, Pink1/Dj1Estados Unidos
-
Ahram Canadian UniversityAin Shams UniversityRecrutamentoDoença de Parkinson | Parkinson | Doença de Parkinson e ParkinsonismoEgito
-
Samuel Vilchez, PhDNational Autonomous University of Nicaragua; Wake Forest University; GID BIO,... e outros colaboradoresConcluídoDoença de Parkinson e Parkinsonismo | Doença de Parkinson IdiopáticaNicarágua
-
King's College LondonGlaxoSmithKlineConcluídoDoença de Parkinson | Doença de Parkinson Idiopática | Doença de Parkinson, PARK8Reino Unido
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationDesconhecidoControles Saudáveis | Doença de Parkinson com mutação LRRK2 | Doença de Parkinson sem mutação LRRK2França
-
Professor Lu Neurological ClinicDesconhecidoDoença de Parkinson de Início PrecoceTaiwan
-
PureIMS B.V.Cooperative Clinical Drug Research and Development AG (CCDRD AG)ConcluídoDoença de Parkinson | Parkinson | Doença de Parkinson e ParkinsonismoBulgária
-
Cedars-Sinai Medical CenterRecrutamentoDistúrbio Comportamental do Sono REM | Doença de Parkinson pré-motora | Doença de Parkinson sintomáticaEstados Unidos